Results were at least partially conflicting in different neoplasia, as OX40 expression is associated with better survival and response to treatment, e.g. in ovarian cancer13, but also with more aggressive diseases, e.g. in breast cancer14,15. Here, TNFRSF4 is linked to neoplasm.